Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Immunochemotherapy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT07822646
What this trial is testing

Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer

Who this might be right for
Ovarian Cancer
Chinese PLA General Hospital 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT05249959
What this trial is testing

Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

Who this might be right for
Relapsed Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
Fondazione Italiana Linfomi - ETS 49
Testing effectiveness (Phase 2)Looking for participantsNCT05699811
What this trial is testing

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid Tumors
Chinese PLA General Hospital 40
Testing effectiveness (Phase 2)UnknownNCT05551767
What this trial is testing

Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer

Who this might be right for
Neck Cancer
City Clinical Oncology Hospital No 1 120
Testing effectiveness (Phase 2)Looking for participantsNCT04745949
What this trial is testing

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy

Who this might be right for
Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell LymphomaAnn Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell LymphomaAnn Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma+1 more
M.D. Anderson Cancer Center
Early research (Phase 1)Not Yet RecruitingNCT07453875
What this trial is testing

LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer

Who this might be right for
Peritoneal Metastasis of Gastric and Colorectal CancerLDRT
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 9
Testing effectiveness (Phase 2)Study completedNCT02221310
What this trial is testing

Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS

Who this might be right for
Acute Myelogenous LeukemiaMyelodysplastic Syndrome
New York Medical College 25
Not applicableLooking for participantsNCT07070011
What this trial is testing

Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer

Who this might be right for
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Shanghai Chest Hospital of Shanghai Jiao Tong University 38
Testing effectiveness (Phase 2)UnknownNCT03719989
What this trial is testing

Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaRelapsed Non Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma
Seoul National University Hospital 27
Large-scale testing (Phase 3)Looking for participantsNCT02657785
What this trial is testing

Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy

Who this might be right for
Primary Central Nervous System Lymphoma
Navy General Hospital, Beijing 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT04506554
What this trial is testing

Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer

Who this might be right for
Muscle-Invasive Bladder Carcinoma
Fox Chase Cancer Center 81
Not applicableUnknownNCT05615103
What this trial is testing

The PET-CT Predicting Response to Immunochemotherapy in Esophageal Cancer

Who this might be right for
Esophageal Cancer
Guangdong Provincial People's Hospital 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06793228
What this trial is testing

Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia

Who this might be right for
SCLC, Extensive Stage
Henan Cancer Hospital 250
Not applicableStudy completedNCT03619993
What this trial is testing

Patient Preference for Pegfilgrastim (Neulasta®) Application Forms

Who this might be right for
Non Hodgkin LymphomaBreast Cancer
iOMEDICO AG 404
Testing effectiveness (Phase 2)Looking for participantsNCT06810609
What this trial is testing

Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC

Who this might be right for
Lung Cancer Non-Small Cell Cancer (NSCLC)
University Hospital, Bonn 176
Not applicableStudy completedNCT07705412
What this trial is testing

Postoperative Radiotherapy and Lymph Node Dissection After Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma (ESCC)
Tongji Hospital 465
Testing effectiveness (Phase 2)UnknownNCT04459611
What this trial is testing

Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）

Who this might be right for
Non-small Cell Lung Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine 60
Not applicableActive Not RecruitingNCT07622693
What this trial is testing

Beta-Blockers on Neoadjuvant Immunochemotherapy for Hypertensive Patients With Gastric Cancer

Who this might be right for
Gastric Cancer (GC)
Nanfang Hospital, Southern Medical University 80
Large-scale testing (Phase 3)Study completedNCT01461928
What this trial is testing

A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab

Who this might be right for
Non-Hodgkin's Lymphoma
Hoffmann-La Roche 692
Testing effectiveness (Phase 2)Study completedNCT01326871
What this trial is testing

ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

Who this might be right for
Transitional Cell Carcinoma of BladderUrethra CancerUreter Cancer+1 more
Altor BioScience 68
Next Page
31